# Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants

> **NCT04073459** · PHASE2 · UNKNOWN · sponsor: **LG Chem** · enrollment: 336 (estimated)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type b Infection

## Interventions

- **BIOLOGICAL:** DTwP-HepB-Sabin IPV-Hib
- **BIOLOGICAL:** Pentavalent vaccine and Salk IPV

## Key facts

- **NCT ID:** NCT04073459
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11
- **Primary completion:** 2020-04
- **Final completion:** 2020-08
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04073459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04073459, "Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04073459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*